Next Article in Journal
Auranofin, an Anti-Rheumatic Gold Compound, Modulates Apoptosis by Elevating the Intracellular Calcium Concentration ([Ca2+]i) in MCF-7 Breast Cancer Cells
Next Article in Special Issue
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Previous Article in Journal
Standard of Care and Promising New Agents for Triple Negative Metastatic Breast Cancer
Previous Article in Special Issue
Comparison of Intracellular Stress Response of NCI-H526 Small Cell Lung Cancer (SCLC) Cells to Platinum(II) Cisplatin and Platinum(IV) Oxoplatin
Open AccessReview

Highlights of the Latest Advances in Research on CDK Inhibitors

1
CALIPHO Group, Swiss Institute of Bioinformatics, CMU-1, rue Michel Servet' Geneva 4 CH-1211, Switzerland
2
MAP Kinase Resource, Bern CH-3027, Switzerland
3
Proteomics Centre, Vilnius University Institute of Biochemistry, Vilnius LT-08662, Lithuania
4
Systems Biomedicine Division and Department of Virology and Immunology, Haffkine Institute for Training Research and Testing, Mumbai 400 012, India
5
Nature Research Centre, Vilnius LT-08412, Lithuania
*
Author to whom correspondence should be addressed.
Cancers 2014, 6(4), 2224-2242; https://doi.org/10.3390/cancers6042224
Received: 25 July 2014 / Revised: 30 September 2014 / Accepted: 14 October 2014 / Published: 27 October 2014
(This article belongs to the Collection Kinases and Cancer)
Uncontrolled proliferation is the hallmark of cancer and other proliferative disorders and abnormal cell cycle regulation is, therefore, common in these diseases. Cyclin-dependent kinases (CDKs) play a crucial role in the control of the cell cycle and proliferation. These kinases are frequently deregulated in various cancers, viral infections, neurodegenerative diseases, ischemia and some proliferative disorders. This led to a rigorous pursuit for small-molecule CDK inhibitors for therapeutic uses. Early efforts to block CDKs with nonselective CDK inhibitors led to little specificity and efficacy but apparent toxicity, but the recent advance of selective CDK inhibitors allowed the first successful efforts to target these kinases for the therapies of several diseases. Major ongoing efforts are to develop CDK inhibitors as monotherapies and rational combinations with chemotherapy and other targeted drugs. View Full-Text
Keywords: cancer; kinase; CDK; small molecule inhibitors cancer; kinase; CDK; small molecule inhibitors
Show Figures

Figure 1

MDPI and ACS Style

Cicenas, J.; Kalyan, K.; Sorokinas, A.; Jatulyte, A.; Valiunas, D.; Kaupinis, A.; Valius, M. Highlights of the Latest Advances in Research on CDK Inhibitors. Cancers 2014, 6, 2224-2242.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop